Passionate and patient-focused. That’s our team.

Passionate and patient-focused. That’s our team.

Herriot Tabuteau, MD


Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012.

Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Nick Pizzie, CPA, MBA


Mr. Pizzie has served as our Chief Financial Officer since May 2018.

Prior to joining Axsome, Mr. Pizzie was the Vice President and Chief Financial Officer of Pierre Fabre USA, the U.S. affiliate of Pierre Fabre. Previously, he was Senior Finance Director at Immucor. Prior to Immucor, he held positions of increasing responsibility in finance and accounting at Merck and Pfizer. Mr. Pizzie began his career at Arthur Andersen, where he served as staff auditor. He earned his BS in Accounting, BA in Economics, and MBA in Finance, and Supply Chain Logistics, from Rutgers University.

Mark Jacobson, MA


Mr. Jacobson has served as Chief Operating Officer since March 2020 and has been a member of the Axsome team since April 2014.

Prior to joining Axsome, he was Director of Corporate Development at Stemline Therapeutics, Inc., where he played a critical role in advancing the company from a 3-person team in 2010 to the successful completion of an initial public offering and secondary public offering in 2013, which together raised approximately $100 million for the company. While at Stemline, Mr. Jacobson’s responsibilities spanned investor relations, public relations, corporate operations, and intellectual property. Mr. Jacobson began his career in healthcare communications at Publicis Healthcare Communications Group. Mr. Jacobson earned a Master of Arts in Biotechnology from Columbia University and a Bachelor of Science in Biology from Iowa State University.

Kevin Laliberte, PharmD


Dr. Laliberte has served as our Executive Vice President, Product Strategy since January 2021.

Prior to joining Axsome, he was Senior Vice President, Product Development at Dova Pharmaceuticals for more than 3 years, where he was responsible for clinical, regulatory, quality, manufacturing, and supply chain. While at Dova, Kevin contributed to the filing and approval of three marketing applications (US, EU, China) and two efficacy supplements for a single product. Prior to Dova, Kevin served 14 years at United Therapeutics with roles of increasing responsibility. For the last 2 years of his tenure as Senior Vice President, Product Development and Clinical Operations, he was responsible for all development activities for small molecules. He earned his Doctor of Pharmacy degree from the University of Michigan, Ann Arbor and completed his post doctorate fellowship at the University of North Carolina, Chapel Hill and GlaxoSmithKline.

Lori Englebert, MBA


Ms. Englebert has served as our Senior Vice President, Commercial and Business Development since August 2020 and has been a member of the Axsome team since September 2019.

Prior to joining Axsome, Ms. Englebert spent 11 years at Amgen where she held leadership positions in commercial, corporate strategy, and business development, including responsibility for multiple commercial product launches. Prior to Amgen, Ms. Englebert started her career at Novartis where she held positions of increasing responsibility in corporate strategy. She earned her BA and MBA from Wake Forest University.

Amanda Jones, PharmD


Dr. Jones has served as our Senior Vice President, Clinical Development since August 2019 and has been a member of the Axsome team since June 2015.

Prior to joining Axsome, she had varying roles of increasing responsibility in clinical research & development at Salix Pharmaceuticals and United Therapeutics. Dr. Jones earned her Doctor of Pharmacy degree from and completed a post-doctoral fellowship in clinical research and drug development at the University of North Carolina Eshelman School of Pharmacy. She earned her Bachelor of Science in Biochemistry from Florida State University.

Cedric O’Gorman, MD, MBA


Dr. O’Gorman has served as our Senior Vice President, Medical Affairs since September 2017.

Prior to joining Axsome, Dr. O’Gorman was the Vice President of Medical Affairs at Intra-Cellular Therapies since December 2014. Before that, he was the U.S. medical lead for psychiatry at Genentech/Roche. Prior to Genentech/Roche, he spent 5 years at Pfizer representing medical affairs on several branded neuroscience products including Geodon for schizophrenia and bipolar disorder, and Pristiq for major depressive disorder. Dr. O’Gorman received his medical degree from the National University of Ireland, in Galway, Ireland, trained at the Institute of Psychiatry, in London, England, and earned his Master of Business Administration from the New York University Stern School of Business.